EvoPreclinical AI
Currently, screening of new antitumor molecules in cell models is carried out manually, taking a lot of time and money and leading to errors. Our solution is to use artificial intelligence to solve this problem! Our products are a screening cell platform for selecting our customers' antitumor molecules, combined with an AI program that makes decisions about the selection of the leader molecule. Thus, our pharmaceutical company clients spend 100-200 times less money and time and make fewer mistakes.
Biotechnology And National Health
Technologies for human health
Within two years 2024-2025, we plan to begin releasing validated screening platforms and AI software for our clients in Russia, China and India (number of clients 50). Within next two years 2026-2027, we plan to begin releasing validated screening platforms and AI software for our clients in Russia, China and India (number of clients 550).
Our products are aimed at the international market. Our clients are pharmaceutical companies located in the BRICS countries. Initially, we plan to attract at least 10 clients of pharmaceutical companies in Russia, providing outsourcing of screening of new antitumor molecules.In 2025, we plan to start sales in China and India for at least 50 customers and increase the number of customers to 200 - 550 by 2027 - 2028.
Existing competing screening platforms do not take into account the role of the most malignant part of the cancer stem cell tumor in chemo- and radioresistance. Also, the assessment of the effect of molecules is carried out at a large cost of man-hours without automating the decision-making system. Our platform evaluates the effect of our clients' molecules on cancer stem cells, allowing you to select leads, future blockbusters on the market. The decision-making system is carried out by AI, saving hundreds of hours of work for customers.
Dr Maria B., MD, PhD, CEO Awards List 2008 INTAS, Oxford, UK Award for the young scientist 2017 Levine Cancer Center, USA “Award for the development of new antitumor molecules against melanoma” 2018 University of North Carolina, USA “Award for the study of the cancer stem cells role in pancreatic cancer” 2022 Sistema Biotech, Russia “For contribution to the development of the company” Media Articles (about Dr Maria Bogachek) Scientists in the Russian Federation create a new way to fight cancer | TV BRICS, 09.04.23 https://tvbrics.com/en/news/scientists-in-the-russian-federation-create-a-new-way-to-fight-cancer/
1. Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors. Bogachek MV et al. Cancer Res. 2015 Jan 2. Targeting the sumoylation pathway in cancer stem cells. Bogachek MV et al. J. Mol Cell Oncol. 2014 3. Sumoylation pathway is required to maintain the basal breast cancer subtype. Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM, Spanheimer PM, Li Y, Li T, Weigel RJ. Cancer Cell. 2014
